Midazolam hydrochloride

Highest phase reached

Approved

www.ebi.ac.uk

Drug type

Small molecule

www.ebi.ac.uk

First approval year

1985

www.ebi.ac.uk

First approval year: 1985
www.ebi.ac.uk

Listing at source: Listed

Highest phase reached: Approved
www.ebi.ac.uk

Drug type: Small molecule
www.ebi.ac.uk

Drug name: Midazolam hydrochloride
www.ebi.ac.uk

Molecular weight: 362.24
www.ebi.ac.uk

Structure (SMILES): Cc1ncc2n1-c1ccc(Cl)cc1C(c1ccccc1F)=NC2.Cl
www.ebi.ac.uk

buccolam
Buccolam
hypnovel
Hypnovel
midazolam hydrochloride
Midazolam hydrochloride
Midazolam hydrochloride (autoinjector)
midazolam hydrochloride autoinjector
midazolam hydrochloride preservative free
Midazolam hydrochloride preservative free
midozalam hydrochloride
Midozalam hydrochloride
seizalam
Seizalam
versed
Versed

8 chloro 6 o fluorophenyl 1 methyl 4h imidazo 1 5 a 1 4 benzodiazepine monohydrochloride
8-Chloro-6-(O-fluorophenyl)-1-methyl-4H-imidazo[1,5-a][1,4]benzodiazepine monohydrochloride
buccolam 10mg
midazolam hcl
Midazolam hcl
midazolam hydrochloride
Midazolam hydrochloride
MIDAZOLAM HYDROCHLORIDE [HSDB]
MIDAZOLAM HYDROCHLORIDE [MART.]
MIDAZOLAM HYDROCHLORIDE [MI]
MIDAZOLAM HYDROCHLORIDE [ORANGE BOOK]
MIDAZOLAM HYDROCHLORIDE [USAN]
MIDAZOLAM HYDROCHLORIDE [VANDF]
Midazolam hydrochloride [WHO-DD]
midazolam hydrochloride civ
Midazolam hydrochloride civ
MIDAZOLAM HYDROCHLORIDE CIV [USP-RS]
midazolam hydrochloride civ usp rs
midazolam hydrochloride hsdb
midazolam hydrochloride mart
midazolam hydrochloride mi
midazolam hydrochloride orange book
midazolam hydrochloride usan
midazolam hydrochloride vandf
midazolam hydrochloride who dd

And 15 more, listed on the interactive page.

CAS registry numbers

59467-96-8

ChEMBL ID: CHEMBL1200420
www.ebi.ac.uk

InChIKey: PLYSCVSCYOQVRP-UHFFFAOYSA-N
www.ebi.ac.uk

FDA ingredient codes (UNII)

W7TTW573JJ

43032
92031775

142441
203128

Applicant: HLR
Approval date: 20 Dec 1985
Application number: NDA018654

First in class: No
Orphan designation: No
Availability: Prescription only
Boxed warning: Yes

Administration routes

Oral
Parenteral

Mechanism
GABA-A receptor; anion channel positive allosteric modulator
Action type
POSITIVE_ALLOSTERIC_MODULATOR
Target
GABA-A receptor; anion channel
Protein identifier
O00591
Mechanism
GABA-A receptor; anion channel positive allosteric modulator
Action type
POSITIVE_ALLOSTERIC_MODULATOR
Target
GABA-A receptor; anion channel
Protein identifier
O14764
Mechanism
GABA-A receptor; anion channel positive allosteric modulator
Action type
POSITIVE_ALLOSTERIC_MODULATOR
Target
GABA-A receptor; anion channel
Protein identifier
P14867
Mechanism
GABA-A receptor; anion channel positive allosteric modulator
Action type
POSITIVE_ALLOSTERIC_MODULATOR
Target
GABA-A receptor; anion channel
Protein identifier
P18505
Mechanism
GABA-A receptor; anion channel positive allosteric modulator
Action type
POSITIVE_ALLOSTERIC_MODULATOR
Target
GABA-A receptor; anion channel
Protein identifier
P18507
Mechanism
GABA-A receptor; anion channel positive allosteric modulator
Action type
POSITIVE_ALLOSTERIC_MODULATOR
Target
GABA-A receptor; anion channel
Protein identifier
P28472
Mechanism
GABA-A receptor; anion channel positive allosteric modulator
Action type
POSITIVE_ALLOSTERIC_MODULATOR
Target
GABA-A receptor; anion channel
Protein identifier
P31644
Mechanism
GABA-A receptor; anion channel positive allosteric modulator
Action type
POSITIVE_ALLOSTERIC_MODULATOR
Target
GABA-A receptor; anion channel
Protein identifier
P34903
Mechanism
GABA-A receptor; anion channel positive allosteric modulator
Action type
POSITIVE_ALLOSTERIC_MODULATOR
Target
GABA-A receptor; anion channel
Protein identifier
P47869
Mechanism
GABA-A receptor; anion channel positive allosteric modulator
Action type
POSITIVE_ALLOSTERIC_MODULATOR
Target
GABA-A receptor; anion channel
Protein identifier
P47870
Mechanism
GABA-A receptor; anion channel positive allosteric modulator
Action type
POSITIVE_ALLOSTERIC_MODULATOR
Target
GABA-A receptor; anion channel
Protein identifier
P48169
Mechanism
GABA-A receptor; anion channel positive allosteric modulator
Action type
POSITIVE_ALLOSTERIC_MODULATOR
Target
GABA-A receptor; anion channel
Protein identifier
P78334
Mechanism
GABA-A receptor; anion channel positive allosteric modulator
Action type
POSITIVE_ALLOSTERIC_MODULATOR
Target
GABA-A receptor; anion channel
Protein identifier
Q16445
Mechanism
GABA-A receptor; anion channel positive allosteric modulator
Action type
POSITIVE_ALLOSTERIC_MODULATOR
Target
GABA-A receptor; anion channel
Protein identifier
Q8N1C3
Mechanism
GABA-A receptor; anion channel positive allosteric modulator
Action type
POSITIVE_ALLOSTERIC_MODULATOR
Target
GABA-A receptor; anion channel
Protein identifier
Q99928
Mechanism
GABA-A receptor; anion channel positive allosteric modulator
Action type
POSITIVE_ALLOSTERIC_MODULATOR
Target
GABA-A receptor; anion channel
Protein identifier
Q9UN88

Open Targets mechanisms

Mechanism
GABA-A receptor; anion channel positive allosteric modulator
Action type
POSITIVE ALLOSTERIC MODULATOR
Target
GABA-A receptor; anion channel

Condition
Dermatitis, Atopic
Highest recorded phase
1
Condition identifier
EFO:0000274
Subject identifier
D003876
Condition
Neoplasms
Highest recorded phase
1
Condition identifier
EFO:0000616
Subject identifier
D009369
Condition
Nervous System Diseases
Highest recorded phase
3
Condition identifier
EFO:0000618
Subject identifier
D009422
Condition
Adenomatous Polyposis Coli
Highest recorded phase
2
Condition identifier
EFO:0000662
Subject identifier
D011125
Condition
Pain
Highest recorded phase
0.5
Condition identifier
EFO:0003843
Subject identifier
D010146
Condition
Status Epilepticus
Highest recorded phase
1
Condition identifier
EFO:0008526
Subject identifier
D013226
Condition
Burns
Highest recorded phase
1
Condition identifier
EFO:0009516
Subject identifier
D002056
Condition
Bipolar Disorder
Highest recorded phase
2
Condition identifier
EFO:0009963
Subject identifier
D001714
Condition
Amnesia
Highest recorded phase
4
Condition identifier
EFO:1001454
Subject identifier
D000647
Condition
Dental Anxiety
Highest recorded phase
2
Condition identifier
EFO:1001884
Subject identifier
D016854
Condition
Epilepsy
Highest recorded phase
4
Condition identifier
HP:0001250
Subject identifier
D004827
Condition
Depressive Disorder, Major
Highest recorded phase
2
Condition identifier
MONDO:0002009
Subject identifier
D003865
Condition
Depressive Disorder
Highest recorded phase
2
Condition identifier
MONDO:0002050
Subject identifier
D003866
Condition
Diabetes Mellitus, Type 2
Highest recorded phase
0.5
Condition identifier
MONDO:0005148
Subject identifier
D003924
Condition
Tuberculosis
Highest recorded phase
1
Condition identifier
MONDO:0018076
Subject identifier
D014376

Condition identifier
EFO_0000474
Highest recorded phase
2
Condition identifier
EFO_0000616
Highest recorded phase
1
Condition identifier
EFO_0000618
Highest recorded phase
3
Condition identifier
EFO_0008526
Highest recorded phase
1
Condition identifier
EFO_0008526
Highest recorded phase
3
Condition identifier
EFO_0009516
Condition identifier
EFO_1001454
Condition identifier
EFO_1001454
Highest recorded phase
4
Condition identifier
HP_0000739
Condition identifier
HP_0001250
Highest recorded phase
4
Condition identifier
HP_0012531
Condition identifier
MONDO_0005027
Highest recorded phase
2
Condition identifier
MONDO_0005148

Warning
Black Box Warning
Warning
Black Box Warning
Effect
misuse
Warning
Black Box Warning
Effect
respiratory toxicity

Warning
Black Box Warning
Country
United States
Warning
Black Box Warning
Effect
misuse
Country
United States
Warning
Black Box Warning
Effect
respiratory toxicity
Country
United States

Event
acidosis hyperchloraemic
Reports
20
Reporting signal score
68.5723
Event
agitation
Reports
159
Reporting signal score
151.427
Event
anaesthetic complication
Reports
37
Reporting signal score
91.0136
Event
anaesthetic complication neurological
Reports
33
Reporting signal score
132.808
Event
anaphylactic reaction
Reports
233
Reporting signal score
313.162
Event
anaphylactic shock
Reports
134
Reporting signal score
222.444
Event
apnoea
Reports
76
Reporting signal score
165.268
Event
bradycardia
Reports
164
Reporting signal score
145.192
Event
bronchospasm
Reports
57
Reporting signal score
69.128
Event
cardiac arrest
Reports
139
Reporting signal score
206.082
Event
cardio-respiratory arrest
Reports
52
Reporting signal score
84.4006
Event
circulatory collapse
Reports
63
Reporting signal score
91.4448
Event
coma
Reports
99
Reporting signal score
90.5121
Event
delayed recovery from anaesthesia
Reports
38
Reporting signal score
131.231
Event
delirium
Reports
153
Reporting signal score
215.98
Event
depressed level of consciousness
Reports
101
Reporting signal score
94.8728
Event
diabetes insipidus
Reports
31
Reporting signal score
73.8373
Event
diarrhoea
Reports
60
Reporting signal score
64.0765
Event
drug reaction with eosinophilia and systemic symptoms
Reports
123
Reporting signal score
162.628
Event
encephalopathy
Reports
67
Reporting signal score
63.6211
Event
fatigue
Reports
32
Reporting signal score
116.837
Event
female genital tract fistula
Reports
24
Reporting signal score
65.205
Event
generalised tonic-clonic seizure
Reports
74
Reporting signal score
108.392
Event
haemodynamic instability
Reports
37
Reporting signal score
63.3091
Event
hyperthermia malignant
Reports
39
Reporting signal score
121.104

And 22 more, listed on the interactive page.

NCT00125424
clinicaltrials.gov
NCT00142493
clinicaltrials.gov
NCT01162486
clinicaltrials.gov
NCT01218620
clinicaltrials.gov
NCT03330990
clinicaltrials.gov
NCT02284204
clinicaltrials.gov
NCT03336450
clinicaltrials.gov
NCT03336645
clinicaltrials.gov
NCT03556592
clinicaltrials.gov
NCT03889756
clinicaltrials.gov
NCT04613453
clinicaltrials.gov
NCT04679623
clinicaltrials.gov
NCT05004896
clinicaltrials.gov
NCT05081583
clinicaltrials.gov
NCT05579509
clinicaltrials.gov
NCT06126991
clinicaltrials.gov

Dose: Up to 2.5mg
Route: Intravenous
How often: Individualized and titrated

Administer over at least 2 minutes
Wait 2+ minutes to evaluate effect

Hydrogen bond acceptors: 3
Hydrogen bond donors: 0
Polar surface area: 30.18
Calculated partition coefficient (ALogP): 4.32
Prodrug: No
Chirality: Achiral
Inorganic: No
Rule-of-five violations: 0
Rotatable bonds: 1
Heavy atoms: 24
Molecular formula: C18H14Cl2FN3
Monoisotopic mass: 361.0548810
Natural product: No

0054-3566
0143-9379
0143-9380
0404-9780
0404-9801
0404-9913
0404-9915
0404-9916
0409-0001
0409-2305
0409-2308
0409-2587
0409-2596
0574-0150
0641-6056
0641-6057
0641-6059
0641-6060
0641-6061
0641-6063
0641-6190
0641-6209
0641-6210
0641-6211
0641-6218

And 46 more, listed on the interactive page.

Recorded assays: 886
Active assays: 37

Confirmatory
Screening
Summary

Adjuvants, Anesthesia
id.nlm.nih.gov
Hypnotics and Sedatives
id.nlm.nih.gov
Anti-Anxiety Agents
id.nlm.nih.gov
Anesthetics, Intravenous
id.nlm.nih.gov
GABA Modulators
id.nlm.nih.gov

Related records

Trials (32)

A PHASE 1, OPEN-LABEL, CROSS-OVER, FIXED SEQUENCE STUDY TO EVALUATE THE EFFECT OF MULTIPLE DOSES OF DS-1971A ON THE SINGLE DOSE PHARMACOKINETICS OF PROBE SUBSTRATES FOR CYP2B6, CYP2C8, CYP2C9, CYP2C19 AND CYP3A4 ENZYMES IN HEALTHY MALE AND FEMALE SUBJECTS
A Study to Investigate the Effects of Multiple Doses of Rezatapopt on the Pharmacokinetics of Metformin, Rosuvastatin, Repaglinide, and Midazolam in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation.
A Trial to Compare the Pharmacokinetics of Two Presentations of Navenibart in Healthy Participants
Assessing the Pharmacokinetics and Drug Interaction Liability of Kratom, an Opioid-like Natural Product
Clinical Evaluation of the Pharmacokinetic Goldenseal-Metformin Interaction in Diabetic Patients
Comparison of Triazolam and Midazolam for Anxiolysis During Dental Treatment in the Pediatric Patient
Comparison of Two Intravenous Drug Combinations for Ambulatory Oral & Maxillofacial Surgery
Drug-drug Interaction Trial With Tralokinumab in Moderate to Severe Atopic Dermatitis - ECZTRA 4
Effect of Affective Content on Drug Induced Amnesia of Episodic Memory
Effects of BI 201335 NA on Cytochrome P450 and P-glycoprotein Activity Using a Probe Drug Cocktail in Healthy Volunteers
Evaluate the Effect of Entrectinib on the Pharmacokinetics of Midazolam in Cancer Patients
Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Advanced Solid Tumors
i-CBT and IV Ketamine for Suicidality in Treatment-Resistant Depression: A Randomized, Midazolam-Controlled Clinical Trial
Inducibility and Stability of Ventricular Tachycardia Inpatients Undergoing VT Ablation Under General Anesthesia
Investigation of Antidepressant Efficacy of Oral Ketamine Treatment
Ketamine for Combined Depression and Alcohol Use Disorder
Ketamine for Methamphetamine Use Disorder
Ketamine for Treatment-Resistant Bipolar Disorder
Ketamine Versus Midazolam for Recurrence of Suicidality in Adolescents
Ketamine With Dialectical Behavioural Therapy (DBT) for Suicidality in Individuals With Treatment-Resistant Depression and Borderline Personality Disorder (KET-DBT)

Approved for (2)

Dissociative amnesia
Epilepsy

In development for (10)

Atopic eczema Phase 1
Bipolar depression Phase 2
Burn Phase 1
Depressive disorder Phase 2
Major depressive disorder Phase 2
Neoplasm Phase 1
Nervous system disorder Phase 3
Polyp Phase 2
Tuberculosis Phase 1
Type 2 diabetes mellitus Early phase 1

Targets (16)

GABRA1 GABA-A receptor; anion channel positive allosteric modulator
GABRA2 GABA-A receptor; anion channel positive allosteric modulator
GABRA3 GABA-A receptor; anion channel positive allosteric modulator
GABRA4 GABA-A receptor; anion channel positive allosteric modulator
GABRA5 GABA-A receptor; anion channel positive allosteric modulator
GABRA6 GABA-A receptor; anion channel positive allosteric modulator
GABRB1 GABA-A receptor; anion channel positive allosteric modulator
GABRB2 GABA-A receptor; anion channel positive allosteric modulator
GABRB3 GABA-A receptor; anion channel positive allosteric modulator
GABRD GABA-A receptor; anion channel positive allosteric modulator
GABRE GABA-A receptor; anion channel positive allosteric modulator
GABRG1 GABA-A receptor; anion channel positive allosteric modulator
GABRG2 GABA-A receptor; anion channel positive allosteric modulator
GABRG3 GABA-A receptor; anion channel positive allosteric modulator
GABRP GABA-A receptor; anion channel positive allosteric modulator
GABRQ GABA-A receptor; anion channel positive allosteric modulator

Midazolam hydrochloride

Development status

Names and chemistry

Brand names (16)

Other names (40)

Identifiers

PubChem compound IDs (2)

RxNorm IDs (RxCUI) (2)

Regulatory information

United States

Other regulatory facts

Pharmacology

Drug classification

Administration routes

Mechanisms of action (16)

Open Targets mechanisms

Investigated indications (15)

Open Targets indications (13)

Warnings (3)

Open Targets warnings (3)

Reported adverse events (47)

Trial references (16)

Dosing

Conditions of use (2)

Chemical properties

National Drug Codes

Evidence counts

Active assay types (3)

Pharmacologic actions

Related records

Trials (32)

Approved for (2)

In development for (10)

Targets (16)